{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T04:48:07Z","timestamp":1744951687128},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T00:00:00Z","timestamp":1681948800000},"content-version":"vor","delay-in-days":109,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Johannes Kepler University Linz"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Der Body-Mass-Index (BMI) ist individuell betrachtet ein sehr grobes Ma\u00df f\u00fcr den Anteil des K\u00f6rperfetts am K\u00f6rpergewicht. Sogar Normalgewichtige k\u00f6nnen bei Muskelmangel zu viel K\u00f6rperfett aufweisen (Sarkopenie), weswegen zus\u00e4tzlich Messungen der K\u00f6rperzusammensetzung (z.\u202fB. Bioimpedanzanalyse [BIA]) empfohlen werden. Lebensstilmanagement mit Ern\u00e4hrungsumstellung und Bewegung ist eine der wichtigsten Ma\u00dfnahmen in der Diabetespr\u00e4vention und -therapie. In der Therapie des Typ-2-Diabetes hat das Gewicht als sekund\u00e4rer Zielparameter zunehmende Bedeutung erlangt. Auch die Wahl der antidiabetischen Therapie, aber auch der Begleittherapien nimmt immer mehr darauf R\u00fccksicht. Die modernen GLP\u20111 Analoga als auch der kombinierte GLP-1\u2013GIP-Agonist Tirzepatid nehmen einen wichtigen Stellenwert in der gemeinsamen Behandlung von Adipositas und Diabetes mellitus Typ\u00a02 ein. Die bariatrische Chirurgie ist derzeit bei an Diabetes mellitus Typ\u00a02 erkrankten Menschen mit BMI &gt;\u202f35\u202fkg\/m<jats:sup>2<\/jats:sup> indiziert und kann zumindest teilweise zur Diabetesremission beitragen, sie muss aber in ein entsprechendes lebenslanges Betreuungskonzept eingebunden sein.<\/jats:p>","DOI":"10.1007\/s00508-023-02184-6","type":"journal-article","created":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T23:03:25Z","timestamp":1682550205000},"page":"91-97","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Adipositas und Typ-2-Diabetes (Update 2023)","Obesity and type\u00a02\u00a0diabetes (Update 2023)"],"prefix":"10.1007","volume":"135","author":[{"given":"Martin","family":"Clodi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hermann","family":"Toplak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Resl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna","family":"Brix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah Raphaela","family":"Leitner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Harreiter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Friedrich","family":"Hoppichler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas C.","family":"Wascher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Schindler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernhard","family":"Ludvik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,4,20]]},"reference":[{"key":"2184_CR1","volume-title":"European heatlh interview survey","author":"EUROSTAT","year":"2016","unstructured":"EUROSTAT. European heatlh interview survey. 2016."},{"issue":"9669","key":"2184_CR2","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/S0140-6736(09)60318-4","volume":"373","author":"Prospective Studies Collaboration","year":"2009","unstructured":"Prospective Studies Collaboration, et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009;373(9669):1083\u201396.","journal-title":"Lancet"},{"issue":"3","key":"2184_CR3","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMp068177","volume":"356","author":"P Hossain","year":"2007","unstructured":"Hossain\u00a0P, Kawar\u00a0B, El Nahas\u00a0M. Obesity and diabetes in the developing world\u2014a growing challenge. N\u00a0Engl J Med. 2007;356(3):213\u20135.","journal-title":"N Engl J Med"},{"issue":"9","key":"2184_CR4","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/S0895-4356(01)00350-X","volume":"54","author":"NB Oldridge","year":"2001","unstructured":"Oldridge\u00a0NB, et al. Prevalence and outcomes of comorbid metabolic and cardiovascular conditions in middle- and older-age adults. J\u00a0Clin Epidemiol. 2001;54(9):928\u201334.","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"2184_CR5","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1159\/000350627","volume":"6","author":"G Fruhbeck","year":"2013","unstructured":"Fruhbeck\u00a0G, et\u00a0al. Obesity: the gateway to ill health\u2014an EASO position statement on a\u00a0rising public health, clinical and scientific challenge in Europe. Obes Facts. 2013;6(2):117\u201320.","journal-title":"Obes Facts"},{"issue":"9765","key":"2184_CR6","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/S0140-6736(10)62037-5","volume":"377","author":"MM Finucane","year":"2011","unstructured":"Finucane\u00a0MM, et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1\u00a0million participants. Lancet. 2011;377(9765):557\u201367.","journal-title":"Lancet"},{"issue":"9","key":"2184_CR7","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1038\/ijo.2008.102","volume":"32","author":"T Kelly","year":"2008","unstructured":"Kelly\u00a0T, et\u00a0al. Global burden of obesity in 2005 and projections to 2030. Int J Obes. 2008;32(9):1431\u20137.","journal-title":"Int J Obes"},{"key":"2184_CR8","volume-title":"Obesity and overweight fact sheet no.311","author":"WHO","year":"2016","unstructured":"WHO. Obesity and overweight fact sheet no.311. 2016."},{"issue":"2","key":"2184_CR9","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1038\/ijo.2011.100","volume":"36","author":"J Gomez-Ambrosi","year":"2012","unstructured":"Gomez-Ambrosi\u00a0J, et al. Body mass index classification misses subjects with increased cardiometabolic risk factors related to elevated adiposity. Int J Obes. 2012;36(2):286\u201394.","journal-title":"Int J Obes"},{"issue":"4","key":"2184_CR10","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1093\/ageing\/afq034","volume":"39","author":"AJ Cruz-Jentoft","year":"2010","unstructured":"Cruz-Jentoft\u00a0AJ, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European working group on sarcopenia in older people. Age Ageing. 2010;39(4):412\u201323.","journal-title":"Age Ageing"},{"issue":"5","key":"2184_CR11","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1111\/j.1532-5415.2007.01140.x","volume":"55","author":"MJ Delmonico","year":"2007","unstructured":"Delmonico\u00a0MJ, et\u00a0al. Alternative definitions of sarcopenia, lower extremity performance, and functional impairment with aging in older men and women. J\u00a0Am Geriatr Soc. 2007;55(5):769\u201374.","journal-title":"J Am Geriatr Soc"},{"issue":"10","key":"2184_CR12","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1093\/gerona\/61.10.1059","volume":"61","author":"BH Goodpaster","year":"2006","unstructured":"Goodpaster\u00a0BH, et\u00a0al. The loss of skeletal muscle strength, mass, and quality in older adults: the health, aging and body composition study. J\u00a0Gerontol A Biol Sci Med Sci. 2006;61(10):1059\u201364.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"9403","key":"2184_CR13","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0140-6736(03)15268-3","volume":"363","author":"WHO Expert Consultation","year":"2004","unstructured":"WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363(9403):157\u201363.","journal-title":"Lancet"},{"issue":"2","key":"2184_CR14","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1159\/000126822","volume":"1","author":"C Tsigos","year":"2008","unstructured":"Tsigos\u00a0C, et\u00a0al. Management of obesity in adults: European clinical practice guidelines. Obes Facts. 2008;1(2):106\u201316.","journal-title":"Obes Facts"},{"issue":"2","key":"2184_CR15","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1159\/000362191","volume":"7","author":"V Yumuk","year":"2014","unstructured":"Yumuk\u00a0V, et\u00a0al. An EASO position statement on multidisciplinary obesity management in adults. Obes Facts. 2014;7(2):96\u2013101.","journal-title":"Obes Facts"},{"issue":"4","key":"2184_CR16","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s13539-014-0161-y","volume":"5","author":"JE Morley","year":"2014","unstructured":"Morley\u00a0JE, Anker\u00a0SD, von Haehling\u00a0S. Prevalence, incidence, and clinical impact of sarcopenia: facts, numbers, and epidemiology-update 2014. J\u00a0Cachexia Sarcopenia Muscle. 2014;5(4):253\u20139.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"1","key":"2184_CR17","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/jcsm.12048","volume":"7","author":"TK Malmstrom","year":"2016","unstructured":"Malmstrom\u00a0TK, et al. SARC-F: a\u00a0symptom score to predict persons with sarcopenia at risk for poor functional outcomes. J\u00a0Cachexia Sarcopenia Muscle. 2016;7(1):28\u201336.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"5","key":"2184_CR18","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1177\/1557988314567223","volume":"10","author":"SA Tsai","year":"2016","unstructured":"Tsai\u00a0SA, et al. Gender differences in weight-related attitudes and behaviors among overweight and obese adults in the United States. Am J Mens Health. 2016;10(5):389\u201398.","journal-title":"Am J Mens Health"},{"issue":"1","key":"2184_CR19","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1159\/000373905","volume":"8","author":"C Grebitus","year":"2015","unstructured":"Grebitus\u00a0C, Hartmann\u00a0M, Reynolds\u00a0N. Global obesity study on drivers for weight reduction strategies. Obes Facts. 2015;8(1):77\u201386.","journal-title":"Obes Facts"},{"issue":"6","key":"2184_CR20","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1159\/000442721","volume":"8","author":"V Yumuk","year":"2015","unstructured":"Yumuk\u00a0V, et\u00a0al. European guidelines for obesity management in adults. Obes Facts. 2015;8(6):402\u201324.","journal-title":"Obes Facts"},{"issue":"4","key":"2184_CR21","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1080\/07315724.2014.911668","volume":"33","author":"TP Wycherley","year":"2014","unstructured":"Wycherley\u00a0TP, et al. Long-term effects of a\u00a0very low-carbohydrate weight loss diet on exercise capacity and tolerance in overweight and obese adults. J\u00a0Am Coll Nutr. 2014;33(4):267\u201373.","journal-title":"J Am Coll Nutr"},{"issue":"12","key":"2184_CR22","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1007\/s11695-014-1299-6","volume":"24","author":"M Otto","year":"2014","unstructured":"Otto\u00a0M, et\u00a0al. Handgrip strength as a\u00a0predictor for post bariatric body composition. Obes Surg. 2014;24(12):2082\u20138.","journal-title":"Obes Surg"},{"issue":"2","key":"2184_CR23","doi-asserted-by":"publisher","first-page":"S392","DOI":"10.2337\/dc09-S346","volume":"32","author":"V Hainer","year":"2009","unstructured":"Hainer\u00a0V, Toplak\u00a0H, Stich\u00a0V. Fat or fit: what is more important? Diabetes Care. 2009;32(2):S392\u20137.","journal-title":"Diabetes Care"},{"issue":"8","key":"2184_CR24","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1111\/j.1532-5415.2009.02366.x","volume":"57","author":"PM Cawthon","year":"2009","unstructured":"Cawthon\u00a0PM, et\u00a0al. Do muscle mass, muscle density, strength, and physical function similarly influence risk of hospitalization in older adults? J\u00a0Am Geriatr Soc. 2009;57(8):1411\u20139.","journal-title":"J Am Geriatr Soc"},{"issue":"4","key":"2184_CR25","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/s00125-010-2027-y","volume":"54","author":"RN Larsen","year":"2011","unstructured":"Larsen\u00a0RN, et al. The effect of high-protein, low-carbohydrate diets in the treatment of type 2 diabetes: a\u00a012\u00a0month randomised controlled trial. Diabetologia. 2011;54(4):731\u201340.","journal-title":"Diabetologia"},{"issue":"3","key":"2184_CR26","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1056\/NEJMoa0708681","volume":"359","author":"I Shai","year":"2008","unstructured":"Shai\u00a0I, et al. Weight loss with a\u00a0low-carbohydrate, Mediterranean, or low-fat diet. N\u00a0Engl J Med. 2008;359(3):229\u201341.","journal-title":"N Engl J Med"},{"issue":"4","key":"2184_CR27","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s00125-012-2461-0","volume":"55","author":"JD Krebs","year":"2012","unstructured":"Krebs\u00a0JD, et al. The diabetes excess weight loss (DEWL) trial: a\u00a0randomised controlled trial of high-protein versus high-carbohydrate diets over 2\u00a0years in type 2 diabetes. Diabetologia. 2012;55(4):905\u201314.","journal-title":"Diabetologia"},{"issue":"5","key":"2184_CR28","doi-asserted-by":"publisher","first-page":"306","DOI":"10.7326\/0003-4819-151-5-200909010-00004","volume":"151","author":"K Esposito","year":"2009","unstructured":"Esposito\u00a0K, et al. Effects of a\u00a0Mediterranean-style diet on the need for antihyperglycemic drug therapy in patients with newly diagnosed type 2 diabetes: a\u00a0randomized trial. Ann Intern Med. 2009;151(5):306\u201314.","journal-title":"Ann Intern Med"},{"issue":"1","key":"2184_CR29","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1001\/jama.293.1.43","volume":"293","author":"ML Dansinger","year":"2005","unstructured":"Dansinger\u00a0ML, et\u00a0al. Comparison of the Atkins, Ornish, weight watchers, and zone diets for weight loss and heart disease risk reduction: a\u00a0randomized trial. JAMA. 2005;293(1):43\u201353.","journal-title":"JAMA"},{"issue":"4","key":"2184_CR30","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/oby.2008.637","volume":"17","author":"TA Wadden","year":"2009","unstructured":"Wadden\u00a0TA, et al. One-year weight losses in the Look AHEAD study: factors associated with success. Obesity (Silver Spring). 2009;17(4):713\u201322.","journal-title":"Obesity (Silver Spring)"},{"issue":"4","key":"2184_CR31","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/s41430-020-00783-4","volume":"75","author":"M Halle","year":"2021","unstructured":"Halle\u00a0M, et al. Meal replacement by formula diet reduces weight more than a\u00a0lifestyle intervention alone in patients with overweight or obesity and accompanied cardiovascular risk factors-the ACOORH trial. Eur J Clin Nutr. 2021;75(4):661\u20139.","journal-title":"Eur J Clin Nutr"},{"issue":"5","key":"2184_CR32","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1159\/000480525","volume":"10","author":"DR Leitner","year":"2017","unstructured":"Leitner\u00a0DR, et\u00a0al. Obesity and type 2 diabetes: two diseases with a\u00a0need for combined treatment strategies\u2014EASO can lead the way. Obes Facts. 2017;10(5):483\u201392.","journal-title":"Obes Facts"},{"key":"2184_CR33","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1475-2840-7-22","volume":"7","author":"W Zidek","year":"2008","unstructured":"Zidek\u00a0W, et al. First-line antihypertensive treatment in patients with pre-diabetes: rationale, design and baseline results of the ADaPT investigation. Cardiovasc Diabetol. 2008;7:22.","journal-title":"Cardiovasc Diabetol"},{"issue":"12","key":"2184_CR34","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.2337\/diacare.26.12.3230","volume":"26","author":"J Lindstrom","year":"2003","unstructured":"Lindstrom\u00a0J, et al. The Finnish diabetes prevention study (DPS): lifestyle intervention and 3\u2011year results on diet and physical activity. Diabetes Care. 2003;26(12):3230\u20136.","journal-title":"Diabetes Care"},{"issue":"6","key":"2184_CR35","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJMoa012512","volume":"346","author":"WC Knowler","year":"2002","unstructured":"Knowler\u00a0WC, et\u00a0al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N\u00a0Engl J Med. 2002;346(6):393\u2013403.","journal-title":"N Engl J Med"},{"issue":"3","key":"2184_CR36","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/j.1464-5491.1990.tb01375.x","volume":"7","author":"ME Lean","year":"1990","unstructured":"Lean\u00a0ME, et\u00a0al. Obesity, weight loss and prognosis in type 2 diabetes. Diabet Med. 1990;7(3):228\u201333.","journal-title":"Diabet Med"},{"issue":"10","key":"2184_CR37","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.2337\/diacare.23.10.1499","volume":"23","author":"DF Williamson","year":"2000","unstructured":"Williamson\u00a0DF, et\u00a0al. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care. 2000;23(10):1499\u2013504.","journal-title":"Diabetes Care"},{"issue":"7","key":"2184_CR38","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.2337\/dc10-2415","volume":"34","author":"RR Wing","year":"2011","unstructured":"Wing\u00a0RR, et\u00a0al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011;34(7):1481\u20136.","journal-title":"Diabetes Care"},{"issue":"17","key":"2184_CR39","first-page":"1566","volume":"170","author":"ARG Look","year":"2010","unstructured":"Look\u00a0ARG, Wing\u00a0RR. Long-term effects of a\u00a0lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look\u00a0AHEAD trial. Arch Intern Med. 2010;170(17):1566\u201375.","journal-title":"Arch Intern Med"},{"issue":"17","key":"2184_CR40","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1001\/archinternmed.2009.266","volume":"169","author":"GD Foster","year":"2009","unstructured":"Foster\u00a0GD, et\u00a0al. A randomized study on the effect of weight loss on obstructive sleep apnea among obese patients with type 2 diabetes: the Sleep AHEAD study. Arch Intern Med. 2009;169(17):1619\u201326.","journal-title":"Arch Intern Med"},{"issue":"6","key":"2184_CR41","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.2337\/dc13-1928","volume":"37","author":"RR Rubin","year":"2014","unstructured":"Rubin\u00a0RR, et al. Impact of intensive lifestyle intervention on depression and health-related quality of life in type 2 diabetes: the Look AHEAD Trial. Diabetes Care. 2014;37(6):1544\u201353.","journal-title":"Diabetes Care"},{"issue":"10120","key":"2184_CR42","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S0140-6736(17)33102-1","volume":"391","author":"ME Lean","year":"2018","unstructured":"Lean\u00a0ME, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet. 2018;391(10120):541\u201351.","journal-title":"Lancet"},{"issue":"3","key":"2184_CR43","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1159\/000430801","volume":"8","author":"H Toplak","year":"2015","unstructured":"Toplak\u00a0H, et al. 2014 EASO position statement on the use of anti-obesity drugs. Obes Facts. 2015;8(3):166\u201374.","journal-title":"Obes Facts"},{"issue":"5","key":"2184_CR44","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1111\/j.1464-5491.2004.01474.x","volume":"22","author":"C Berne","year":"2005","unstructured":"Berne\u00a0C, Orlistat Swedish Type 2 diabetes Study Group. A randomized study of orlistat in combination with a\u00a0weight management programme in obese patients with type 2 diabetes treated with metformin. Diabet Med. 2005;22(5):612\u20138.","journal-title":"Diabet Med"},{"issue":"12","key":"2184_CR45","doi-asserted-by":"publisher","first-page":"4022","DOI":"10.2337\/dc13-0234","volume":"36","author":"P Hollander","year":"2013","unstructured":"Hollander\u00a0P, et al. Effects of naltrexone sustained-release\/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013;36(12):4022\u20139.","journal-title":"Diabetes Care"},{"issue":"7","key":"2184_CR46","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1001\/jama.2015.9676","volume":"314","author":"MJ Davies","year":"2015","unstructured":"Davies\u00a0MJ, et\u00a0al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA. 2015;314(7):687\u201399.","journal-title":"JAMA"},{"issue":"22","key":"2184_CR47","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1916038","volume":"382","author":"AS Kelly","year":"2020","unstructured":"Kelly\u00a0AS, et\u00a0al. A randomized, controlled trial of liraglutide for adolescents with obesity. N\u00a0Engl J Med. 2020;382(22):2117\u201328.","journal-title":"N Engl J Med"},{"issue":"10278","key":"2184_CR48","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","volume":"397","author":"M Davies","year":"2021","unstructured":"Davies\u00a0M, et al. Semaglutide 2.4\u202fmg once a\u00a0week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a\u00a0randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971\u201384.","journal-title":"Lancet"},{"issue":"24","key":"2184_CR49","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1056\/NEJMoa2208601","volume":"387","author":"D Weghuber","year":"2022","unstructured":"Weghuber\u00a0D, et al. Once-weekly semaglutide in adolescents with obesity. N\u00a0Engl J Med. 2022;387(24):2245\u201357.","journal-title":"N Engl J Med"},{"issue":"10295","key":"2184_CR50","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","volume":"398","author":"J Rosenstock","year":"2021","unstructured":"Rosenstock\u00a0J, et al. Efficacy and safety of a\u00a0novel dual GIP and GLP\u20111 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a\u00a0double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143\u201355.","journal-title":"Lancet"},{"issue":"6","key":"2184_CR51","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","volume":"385","author":"JP Frias","year":"2021","unstructured":"Frias\u00a0JP, et\u00a0al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N\u00a0Engl J Med. 2021;385(6):503\u201315.","journal-title":"N Engl J Med"},{"issue":"6","key":"2184_CR52","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1001\/jama.2022.0078","volume":"327","author":"D Dahl","year":"2022","unstructured":"Dahl\u00a0D, et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS\u20115 randomized clinical trial. JAMA. 2022;327(6):534\u201345.","journal-title":"JAMA"},{"issue":"26","key":"2184_CR53","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1056\/NEJMoa035622","volume":"351","author":"L Sjostrom","year":"2004","unstructured":"Sjostrom\u00a0L, et\u00a0al. Lifestyle, diabetes, and cardiovascular risk factors 10\u00a0years after bariatric surgery. N\u00a0Engl J Med. 2004;351(26):2683\u201393.","journal-title":"N Engl J Med"},{"issue":"11","key":"2184_CR54","doi-asserted-by":"publisher","first-page":"S89","DOI":"10.1210\/jc.2008-1641","volume":"93","author":"WJ Pories","year":"2008","unstructured":"Pories\u00a0WJ. Bariatric surgery: risks and rewards. J\u00a0Clin Endocrinol Metab. 2008;93(11):S89\u201396.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2184_CR55","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/joim.12012","volume":"273","author":"L Sjostrom","year":"2013","unstructured":"Sjostrom\u00a0L. Review of the key results from the Swedish obese subjects (SOS) trial\u2014a\u00a0prospective controlled intervention study of bariatric surgery. J\u00a0Intern Med. 2013;273(3):219\u201334.","journal-title":"J Intern Med"},{"issue":"11","key":"2184_CR56","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1001\/2012.jama.11792","volume":"308","author":"M Neovius","year":"2012","unstructured":"Neovius\u00a0M, et\u00a0al. Health care use during 20\u00a0years following bariatric surgery. JAMA. 2012;308(11):1132\u201341.","journal-title":"JAMA"},{"issue":"1","key":"2184_CR57","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.clnu.2015.02.012","volume":"35","author":"R Thibault","year":"2016","unstructured":"Thibault\u00a0R, et\u00a0al. Twelve key nutritional issues in bariatric surgery. Clin Nutr. 2016;35(1):12\u20137.","journal-title":"Clin Nutr"},{"issue":"6","key":"2184_CR58","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1159\/000481825","volume":"10","author":"L Busetto","year":"2017","unstructured":"Busetto\u00a0L, et al. Practical recommendations of the obesity management task force of the European association for the study of obesity for the post-bariatric surgery medical management. Obes Facts. 2017;10(6):597\u2013632.","journal-title":"Obes Facts"},{"issue":"7","key":"2184_CR59","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1007\/s11695-018-3283-z","volume":"28","author":"L Busetto","year":"2018","unstructured":"Busetto\u00a0L, et al. Obesity management task force of the European association for the study of obesity released \u201epractical recommendations for the post-bariatric surgery medical management\u201c. Obes Surg. 2018;28(7):2117\u201321.","journal-title":"Obes Surg"},{"issue":"7","key":"2184_CR60","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1007\/s00125-015-3591-y","volume":"58","author":"K Sjoholm","year":"2015","unstructured":"Sjoholm\u00a0K, et\u00a0al. Incidence and remission of type 2 diabetes in relation to degree of obesity at baseline and 2\u00a0year weight change: the Swedish obese subjects (SOS) study. Diabetologia. 2015;58(7):1448\u201353.","journal-title":"Diabetologia"},{"issue":"6","key":"2184_CR61","doi-asserted-by":"publisher","first-page":"861","DOI":"10.2337\/dc16-0236","volume":"39","author":"F Rubino","year":"2016","unstructured":"Rubino\u00a0F, et\u00a0al. Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations. Diabetes Care. 2016;39(6):861\u201377.","journal-title":"Diabetes Care"},{"issue":"7","key":"2184_CR62","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.3949\/ccjm.84.s1.06","volume":"84","author":"PR Schauer","year":"2017","unstructured":"Schauer\u00a0PR, Nor Hanipah\u00a0Z, Rubino\u00a0F. Metabolic surgery for treating type 2 diabetes mellitus: now supported by the world\u2019s leading diabetes organizations. Cleve Clin J Med. 2017;84(7):S47\u2013S56.","journal-title":"Cleve Clin J Med"},{"issue":"3","key":"2184_CR63","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.amjmed.2008.09.041","volume":"122","author":"H Buchwald","year":"2009","unstructured":"Buchwald\u00a0H, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009;122(3):248\u2013256.e5.","journal-title":"Am J Med"},{"issue":"14","key":"2184_CR64","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1001\/jama.292.14.1724","volume":"292","author":"H Buchwald","year":"2004","unstructured":"Buchwald\u00a0H, et al. Bariatric surgery: a\u00a0systematic review and meta-analysis. JAMA. 2004;292(14):1724\u201337.","journal-title":"JAMA"},{"issue":"7","key":"2184_CR65","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1056\/NEJMoa1600869","volume":"376","author":"PR Schauer","year":"2017","unstructured":"Schauer\u00a0PR, et al. Bariatric surgery versus intensive medical therapy for diabetes\u20145-year outcomes. N\u00a0Engl J Med. 2017;376(7):641\u201351.","journal-title":"N Engl J Med"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-023-02184-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00508-023-02184-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-023-02184-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T23:06:33Z","timestamp":1682550393000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00508-023-02184-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":65,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["2184"],"URL":"https:\/\/doi.org\/10.1007\/s00508-023-02184-6","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"28 February 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.\u00a0Clodi hat von folgenden Unternehmen, die auch f\u00f6rdernde Mitglieder der \u00d6DG sind, Forschungsunterst\u00fctzungen und\/oder Honorare erhalten: Abbott Diabetes Care, AstraZeneca, Boehringer Ingelheim, Daiichi-Sankyo, Dexcom, Eli Lilly, Medtronic, MSD, Novartis, Novo Nordisk, Sanofi. H.\u00a0Toplak hat von folgenden Unternehmen, Forschungsunterst\u00fctzungen und\/oder Honorare erhalten: Almased, Bodymed, Cheplapharm, Eli Lilly, Insumed, MSD, Mylan, Novartis, Novo Nordisk, Pfizer, Sanofi-Aventis, Servier, Omron, Deutschland, Takeda, Vivus. M.\u00a0Resl hat von folgenden Unternehmen, die teils auch f\u00f6rdernde Mitglieder der \u00d6DG sind, Honorare f\u00fcr Vortr\u00e4ge und\/oder Beratert\u00e4tigkeit bzw. Fortbildungsunterst\u00fctzung erhalten Boehringer Ingelheim, Mylan, Dexcom, Abbott J.\u00a0Brix: Honorare f\u00fcr Advisory Boards und Vortr\u00e4ge von Astra Zeneca, Boehringer-Ingelheim, Eli Lilly, Novo Nordisk, Sanofi. D.R.\u00a0Leitner hat von folgenden Unternehmen Forschungsunterst\u00fctzungen und\/oder Honorare erhalten: Novo Nordisk. J.\u00a0Harreiter hat Forschungsf\u00f6rderung und Vortragshonorare bzw. Fortbildungsf\u00f6rderung (Kongressunterst\u00fctzung) von den Firmen Astra Zeneca, Novo Nordisk und B\u00f6hringer Ingelheim erhalten. F.\u00a0Hoppichler hat Forschungsf\u00f6rderung und Vortragshonorer von folgenden Firmen erhalten: Boehringer Ingelheim RCV GmbH & Co KG, Sanofi-Aventis GmbH, Daiichi Sankyo Austria GmbH, AstraZeneca \u00d6sterreich GmbH, Amgen GmbH, Novo Nordisk Pharma GmbH, Eli Lilly Gesellschaft Gm.b.H. T.C.\u00a0Wascher hat Forschungsunterst\u00fctzung, Honorare f\u00fcr Beratung oder Fortbildung erhalten von Boehringer Ingelheim, Astra Zeneca, Ely Lilly, Novo Nordisk. K.\u00a0Schindler gibt an, dass kein Interessenkonflikt besteht. B.\u00a0Ludvik erhielt Honorare f\u00fcr Vortr\u00e4ge, die Teilnahme an Advisory Boards und Forschungsunterst\u00fctzung von: Amgen, Astra Zeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, MSD, Novartis, Novo Nordisk, Sanofi.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}